Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169620 | 0.94 | PDE4A (0.58) | PDE4AKCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL7167992 | 0.89 | PDE4A (0.53) | PDE4AKCNH2HDAC1HDAC2 | |
| SCHEMBL7169490 | 0.88 | PDE4A (0.53) | PDE4AKCNH2HDAC1HDAC2 | |
| SCHEMBL7688432 | 0.87 | PDE4A (0.55) | PDE4AKCNH2LMNAHDAC1HDAC2 | |
| SCHEMBL7172789 | 0.83 | PDE4A (0.57) | PDE4AKCNH2LMNAHSD17B10 | |
| SCHEMBL7171340 | 0.83 | PDE4A (0.71) | PDE4AKCNH2 | |
| SCHEMBL7169759 | 0.82 | PDE4A (0.62) | PDE4AKCNH2MEN1KMT2A | |
| SCHEMBL7169919 | 0.82 | PDE4A (0.62) | PDE4AKCNH2 | |
| SCHEMBL7172514 | 0.82 | PDE4A (0.60) | PDE4AKCNH2KMT2ALMNATP53 | |
| SCHEMBL7172813 | 0.82 | PDE4A (0.82) | PDE4AKCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | PDE4A 4/4885KCNH2 559/4885MEN1 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.